The Head of the Federal Medical-Biological Agency (FMBA) announced… (вакцина · фмба · онкорн)
The Head of the Federal Medical-Biological Agency (FMBA) announced the application of a Russian cancer vaccine in early stages. 'Onkorna' has become the second approved personalized vaccine for colorectal cancer therapy; the FMBA also holds approval to use the peptide therapeutic vaccine 'Oncopept'.
Consensus
- The Russian mRNA vaccine 'Onkorna' against colorectal cancer can be used in earlier stages of treatment.
- The vaccine is approved for use in cases with confirmed microsatellite instability.
- The vaccine is a personalized treatment based on mRNA technology.
- The Federal Medical and Biological Agency (FMBA) approved 'Onkorna' for clinical use in April.
- Russia has developed two cancer vaccines for glioblastoma: 'Gliopent' and 'Gliorna'.
Points of divergence
- The vaccine 'Onkorna' is the first Russian mRNA-based vaccine against colorectal cancer. — vedomosti
- Russia may have its first domestic vaccines for glioblastoma in the near future. — vedomosti
- Russia has developed diagnostic methods for glioma using PET/CT with new radiopharmaceuticals and GQ comby. — vedomosti
- The vaccine 'Onkorna' is the second personalized vaccine approved by FMBA for colorectal cancer treatment. — kommersant